Alexandros Makriyannis
Has grant
Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Training Program on Development of Medications for Substance Use Disorder
Open Date: 2022-07-01
Close Date: 2027-06-30
Grant: Close
CB1 Neutral Antagonists for Alcohol Use Disorder
Open Date: 2020-09-20
Close Date: 2026-08-31
Grant: Close
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
Open Date: 2020-07-01
Close Date: 2026-05-31
Grant: Close
Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases
Open Date: 2019-09-01
Close Date: 2021-08-31
Grant: Close
Medications for Synthetic Cannabinoid Abuse
Open Date: 2019-03-01
Close Date: 2022-02-28
Articles (21)
Year:
2026
Year:
2025
Year:
2025
Virtual library docking can reveal unexpected chemotypes that complement the structures of biological targets. Seeking agonists for the cannabinoid-1 receptor (CB1R), we dock 74 million tangible molecules and prioritize 46 high ranking ones for de novo synthesis and testing. Nine are active by radioligand competition, a 20% hit-rate. Structure-based optimization of one of the most potent of these (K i = 0.7 µM) leads to ‘1350, a 0.95 nM ligand and a full CB1R agonist of G i/o signaling. A cryo-EM structure of ‘1350 in complex with CB1R-G i1 confirms its predicted docked pose. The lead agonist is strongly analgesic in male mice, with a 2-20-fold therapeutic window over hypolocomotion, sedation, and catalepsy and no observable conditioned place preference. These findings suggest that unique cannabinoid chemotypes may disentangle characteristic cannabinoid side-effects from analgesia, supporting the further development of cannabinoids as pain therapeutics.
Year:
2025
Tetrahydrocannabinol (THC) is the principal psychoactive compound derived from the cannabis plant Cannabis sativa and approved for emetic conditions, appetite stimulation and sleep apnea relief. THC’s psychoactive actions are mediated primarily by the cannabinoid receptor CB 1 . Here, we determine the cryo-EM structure of HU210, a THC analog and widely used tool compound, bound to CB 1 and its primary transducer, G i1 . We leverage this structure for docking and 1000 ns molecular dynamics simulations of THC and 10 structural analogs delineating their spatiotemporal interactions at the molecular level. Furthermore, we pharmacologically profile their recruitment of G i and β-arrestins and reversibility of binding from an active complex. By combining detailed CB 1 structural information with molecular models and signaling data we uncover the differential spatiotemporal interactions these ligands make to receptors governing potency, efficacy, bias and kinetics. This may help explain the actions of abused substances, advance fundamental receptor activation studies and design better medicines.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (15)
Andrea G. Hohmann
Linda and Jack Gill Chair and Professor
Indiana University Bloomington
Poul Nissen
Vice-Dean for Research
Aarhus University
Zheng-Xiong Xi
National Institute on Drug Abuse Intramural Research Program
Christos Iliopoulos_Tsoutsouvas
Research Assistant Professor
Northeastern University
Thomas Boesen
Aarhus University
Fangyu Liu
Assistant Professor
University of Texas Southwestern Medical Center
Michael Gajhede
Professor
Københavns Universitet
David Gloriam
Københavns Universitet
Laura Bohn
Professor, Associate Dean of Basic and Translational Medicine
Scripps Florida
Vsevolod Katritch
University of Southern California
Ken Mackie
University of Washington Medical Center
Evan O'Brien
Assistant Professor
Johns Hopkins University
Dmitry Veprintsev
Professor of Molecular and Cellular Pharmacology
University of Nottingham
Mario van der Stelt
-
Fei Tong
Northeastern University
Make your next move.
Prepare your application
Review drafts before you send them.